NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco
California
94080
United States
138 articles about NGM Biopharmaceuticals, Inc.
-
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial
4/24/2017
-
NGM Initiates Phase 1 Clinical Trial Of NGM313, A Proprietary Antibody With The Potential To Treat Type 2 Diabetes, Obesity And NASH
6/8/2016
-
Nine Bay Area Biotechs Vie to be the “Next Genentech”
5/26/2016
-
Booming Bay Area Biotech NGM Plans Move to Vacant Site Once Meant for Amgen
5/5/2016
-
NGM To Present New Data On NGM282 At The European Association For The Study Of The Liver International Liver Congress 2015
4/20/2015
-
NGM Announces Positive Phase II Clinical Data In Primary Biliary Cirrhosis Patients For NGM282, A First-In-Class Investigational Medicine
3/24/2015
-
Backed By a Genentech Alum, NGM Looks Like it Could be the Next Biotech IPO
3/5/2015
-
NGM Announces Expansion Of Management Team
3/2/2015
-
How Merck & Co.'s R&D Chief Saved NGM Deal With a Juicy Pitch
2/27/2015
-
Merck & Co. Bets $450 Million on Bay Area's NGM
2/24/2015
-
NGM Biopharmaceuticals, Inc. Locks Down $50 Million Series C
7/18/2013
-
AstraZeneca PLC and NGM Biopharmaceuticals, Inc. Form Diabetes/Obesity Partnership
6/17/2013
-
NGM Biopharmaceuticals, Inc., Led by Genentech Vets Levinson and Goeddel, Raises $13.5 Million
5/6/2013
-
NGM Biopharmaceuticals, Inc., Janssen Pharmaceutical K.K. Form Alliance for Undisclosed Amount
1/3/2013
-
NGM Biopharmaceuticals, Inc. and Daiichi Sankyo, Inc. Collaborate to Discover and Develop Innovative Therapeutics for Diabetes
3/29/2012
-
NGM Biopharmaceuticals, Inc. Names William J. Rieflin Chief Executive Officer and Director
10/5/2010
-
NGM Biopharmaceuticals, Inc. Raises $51 Million in Series B Financing and Appoints New Board Member
3/15/2010
-
NGM Biopharmaceuticals, Inc. Appoints Dr. Arthur D. Levinson, Former Genentech (South SF) CEO, to its Board of Directors
10/21/2009